Berberine Protects Cardiac Cells Against Ferroptosis
Overview
Authors
Affiliations
Objectives: Cardiovascular diseases are one of the primary causes of death. Cardiomyocyte loss is a significant feature of cardiac injury. Ferroptosis is iron-dependent cell death, which occurs due to excess iron and reactive oxygen species (ROS) accumulation causing lipid peroxidation, and subsequent cell death. Ferroptosis has been confirmed to mediate ischemia/reperfusion-induced cardiomyopathy and chemotherapy-induced cardiotoxicity. Berberine (BBR) has been proven to protect the heart from cardiomyopathies, including cardiac hypertrophy, heart failure, myocardial infarction, and arrhythmias. It protects cardiomyocytes from apoptosis and autophagy. However, the relation between BBR and ferroptosis is still unknown. This study aimed to confirm if BBR reduces cardiac cell loss via inhibiting ferroptosis.
Materials And Methods: We used erastin and Ras-selective lethal small molecule 3 (RSL3) to establish a ferroptosis model in an H9c2 cardiomyoblast cell line and rat neonatal cardiomyocytes to prove that BBR has a protective effect on cardiac cells via inhibiting ferroptosis.
Results: In H9c2 cardiomyoblasts, the results showed that BBR reduced erastin and RSL3-induced cell viability loss. Moreover, BBR decreased ROS accumulation and lipid peroxidation in cells induced with ferroptosis. Furthermore, quantitative polymerase chain reaction results showed that mRNA was reduced in BBR-treated cells. In rat neonatal cardiomyocytes, BBR reduced RSL3-induced loss of cell viability.
Conclusion: These results indicated that BBR inhibited ferroptosis via reducing ROS generation and reducing lipid peroxidation in erastin and RSL3-treated cardiac cells.
Chuang Y, Yen C, Chien T, Chang F, Tsai Y, Wu K Int J Mol Sci. 2024; 25(11).
PMID: 38892270 PMC: 11173094. DOI: 10.3390/ijms25116083.
Zhang T, Luo L, He Q, Xiao S, Li Y, Chen J Eur J Med Res. 2024; 29(1):253.
PMID: 38659000 PMC: 11044586. DOI: 10.1186/s40001-024-01809-4.
Zhang X, Sun J, Wang J, Meng T, Yang J, Zhou Y Front Pharmacol. 2023; 14:1286718.
PMID: 37954843 PMC: 10637571. DOI: 10.3389/fphar.2023.1286718.
Wang X, Quan J, Xiu C, Wang J, Zhang J Chin Med. 2023; 18(1):110.
PMID: 37649073 PMC: 10466729. DOI: 10.1186/s13020-023-00819-4.
Iron accumulation and lipid peroxidation: implication of ferroptosis in diabetic cardiomyopathy.
Yan X, Xie Y, Liu H, Huang M, Yang Z, An D Diabetol Metab Syndr. 2023; 15(1):161.
PMID: 37468902 PMC: 10355091. DOI: 10.1186/s13098-023-01135-5.